BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33660894)

  • 1. Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
    McCann C; Matveeva A; McAllister K; Van Schaeybroeck S; Sessler T; Fichtner M; Carberry S; Rehm M; Prehn JHM; Longley DB
    FEBS J; 2021 Sep; 288(18):5374-5388. PubMed ID: 33660894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
    Crawford N; Salvucci M; Hellwig CT; Lincoln FA; Mooney RE; O'Connor CL; Prehn JH; Longley DB; Rehm M
    Cell Death Differ; 2018 Nov; 25(11):1952-1966. PubMed ID: 29500433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.
    Qattan MY; Bakker EY; Rajendran R; Chen DW; Saha V; Liu J; Zeef L; Schwartz JM; Mutti L; Demonacos C; Krstic-Demonacos M
    PLoS One; 2017; 12(6):e0178606. PubMed ID: 28582465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism.
    Lincoln FA; Imig D; Boccellato C; Juric V; Noonan J; Kontermann RE; Allgöwer F; Murphy BM; Rehm M
    Cell Death Dis; 2018 Nov; 9(11):1112. PubMed ID: 30385739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
    Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
    Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.
    An Y; Jeon J; Sun L; Derakhshan A; Chen J; Carlson S; Cheng H; Silvin C; Yang X; Van Waes C; Chen Z
    Sci Rep; 2021 Mar; 11(1):6392. PubMed ID: 33737574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
    Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
    Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
    Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.
    Pilling AB; Hwang O; Boudreault A; Laurent A; Hwang C
    Prostate; 2017 Jun; 77(8):866-877. PubMed ID: 28240376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
    Huang X; Ke K; Jin W; Zhu Q; Zhu Q; Mei R; Zhang R; Yu S; Shou L; Sun X; Feng J; Duan T; Mou Y; Xie T; Wu Q; Sui X
    Front Immunol; 2022; 13():887048. PubMed ID: 35784334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
    Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
    Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
    J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
    Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.